Amidst the volatility of the stock market, the winds of change are blowing favorably for medical technology company Medtronic. The past three years have seen impressive growth in the healthcare sector, where Medtronic, despite facing challenges, has outperformed its peer, Abbott. Let’s delve into why Medtronic emerges as the better investment option compared to Abbott over this period.
Stock Performance Comparison
When it comes to stock returns, Medtronic faced a decline, dropping 25% from early January 2021 to around $85. Meanwhile, Abbott saw little change, maintaining levels of $110 over the same period. This paints a clear picture that Medtronic went through a rougher patch in the stock market compared to Abbott.
Throughout the previous three years, both Medtronic and Abbott underperformed the S&P 500, reflecting the challenging market conditions for healthcare stocks overall. This includes big players like LLY, UNH, JNJ, and even megacap stars GOOG, TSLA, and MSFT. However, amidst this backdrop, Medtronic stood out, showing resilience and stability and is expected to continue to do so.
Abbott’s Revenue Growth
Abbott’s strong suit has been its impressive revenue growth, averaging 11% annually in the last three years, outshining Medtronic’s 3% growth. The surge in COVID-19 testing demand was a significant revenue driver for Abbott, although this trend faltered in 2023 with a sharp decline in diagnostic sales.
On the other hand, Medtronic encountered a slump in sales during the pandemic due to the postponement of elective surgeries. However, the company witnessed a sales rebound in the last couple of years, aided by higher procedure volume. Notably, the company’s new products, including the Micra AV pacemaker and Abre venous self-expanding stent system for Deep Venous disease, have also contributed to its revenue growth.
Medtronic’s Profitability and Risk
Medtronic emerges as the more profitable entity, with an operating margin of around 17.4%, marginally outperforming Abbott’s 16.2%. However, Abbott holds the advantage in terms of financial risk, with lower debt as a percentage of equity at 8% compared to Medtronic’s 22%. Moreover, Abbott also boasts a slightly higher cash cushion at 10% compared to Medtronic’s 9%.
Valuation and Return Expectations
On the basis of valuation multiples, Medtronic holds a slight edge, trading at 3.6x trailing revenues compared to Abbott’s 4.6x. The analysis also indicates a favorable expected return of 13% for Medtronic over the next three years, as opposed to a 6% expected return for Abbott. These numbers demonstrate the promising prospects Medtronic has in store for investors.
As the healthcare industry faces uncertainty amidst high oil prices and elevated interest rates, the prospects for both Medtronic and Abbott appear promising. Despite this, Medtronic is expected to outshine Abbott, offering investors a better avenue for long-term growth.
[1] Returns as of 1/26/2024
[2] Cumulative total returns since the end of 2016
Investing in stocks involves careful evaluation, and Medtronic emerges as the top contender, showcasing resilience, stability, and a promise of better returns. While Medtronic may outperform Abbott, a comprehensive analysis of Medtronic’s peers can provide valuable insights into the company’s market positioning. The landscape of investment options becomes clearer when analyzed alongside prominent industry players.
